Michael Howell

Michael Howell is a seasoned professional in the field of biomedical research with extensive experience in drug discovery, translational science, and clinical development. Currently serving as Chief Scientific Officer and Scientific Advisor at Zura Bio Limited, and as Board Member and Scientific Advisor at Amytrx Therapeutics, Inc., Michael has co-founded Galileo Biosystems and is President of Mountaineer Biosciences, a firm focused on various scientific domains including personalized medicine and diagnostic development. Previous roles include Chief Scientific Officer at DermTech, Senior Director of Translational Research at Incyte, and Principal Scientist/Associate Director at MedImmune. Michael's academic background includes a Ph.D. in Microbiology and Immunology from West Virginia University School of Medicine and a B.S. in Biology and Chemistry from Messiah University.